Greetings Yasufumi Kaneda, Chairman of Japan Society of Gene and Cell Therapy (JSGCT)
September 10th, 2015
To all the members of JSGCT;
I was elected again as a chairman of JSGCT in July 2015. I will continue the chairmanship for three years to 2018. Here, I announce my keynote address to all the members of JSGCT.
Firstly, I would like to stress the importance of basic research to support clinical applications of gene therapy. Every member should always make efforts to address all the concerns in gene therapy by providing scientific evidence. The success of gene therapy results from solid science. Our annual meeting should be an opportunity to enhance gene therapy science.
Secondly, I would like to appeal to the member of our society to improve the level of clinical trials. The quality of clinical tests in Japan was poor in early days of gene therapy. I have claimed the importance of investigator-initiated clinical trials according to ICH-GCP standard. Otherwise, pharmaceutical companies never trust clinical data of gene therapy.
Thirdly, I will continue to accelerate global cooperation in gene therapy. We have invited the president of ASGCT and ESGCT every year and organized international session. ASGCT has continued to hold international session every year and ESGCT has planned joint symposium with JSGCT. Recently, we have had more intimate relationship with ASGCT and ESGCT. Global cooperation should be continuously performed. We have also organized Asian session of gene therapy since 2001. Based on the achievements, we decided to organize the consortium with cooperators in Asian and Pacific countries to further promote gene therapy activities. Last July, we established the Asian-Pacific Consortium of Gene and Cell Therapy (APCGCT). I would like to further promote the activity of APCGCT to accelerate gene therapy in Asian and Pacific counties.
Lastly, my current biggest aim is to launch Japan-original gene therapy products. Promising seeds of gene therapy are growing in Japan, but more support is necessary to obtain funds, to promote Phase II clinical trials and to co-operate with companies. JSGCT will also support investigators in those critical points. If a Japan-original gene therapy product comes out, the atmosphere surrounding gene therapy will be completely changed. This achievement will trigger a revolution of gene therapy in Japan
I will be very grateful, if all the members of JSGTC well understand those policies and co-operate with each other to strengthen gene therapy in Japan.
Chairman of JSGCT
Professor, Division of Gene Therapy Science,
Department of Genome Biology Graduate School of Medicine, Osaka University